SCHEMBL4877217

SCHEMBL4877217

O=C(NS(=O)(=O)O)C1(c2ccccc2)CCN(c2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.50
TET3 O43151 1/20 0.50
FBXL19 Q6PCT2 1/20 0.50
CXXC5 Q7LFL8 1/20 0.50
KDM2B Q8NHM5 1/20 0.50
CXXC4 Q9H2H0 1/20 0.50
KDM2A Q9Y2K7 1/20 0.50
ALDH1A1 P00352 3/20 0.45
MLYCD O95822 1/20 0.45
HDAC4 P56524 2/20 0.44
ELOVL1 Q9BW60 1/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C19 P33261 2/20 0.44
MEN1 O00255 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C9 P11712 2/20 0.43
USP2 O75604 2/20 0.43
HSD11B1 P28845 2/20 0.43
MMP2 P08253 2/20 0.43
MMP13 P45452 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4880538 0.85 SOAT1 (0.50) KMT2AALDH1A1CYP3A4CYP2C19MEN1
SCHEMBL4881130 0.80 DRD2 (0.49) KMT2AMMP2MMP13
SCHEMBL4877226 0.75 SIGMAR1 (0.48) KMT2AALDH1A1CYP3A4CYP2C19MEN1
Hydrochloric Acid SCHEMBL4880947 0.70 SOAT1 (0.51) KMT2AMEN1
SCHEMBL20789429 0.70 KMT2A (0.67) KMT2ATET3FBXL19CXXC5KDM2B
SCHEMBL3281993 0.70 KMT2A (0.58) KMT2ATET3FBXL19CXXC5KDM2B
SCHEMBL3087224 0.69 KMT2A (0.61) KMT2ATET3FBXL19CXXC5KDM2B
SCHEMBL2858838 0.69 MEN1 (0.75) KMT2AALDH1A1HDAC4MEN1USP2
SCHEMBL20491201 0.68 NPSR1 (0.50) KMT2AALDH1A1MLYCDCYP3A4MEN1
SCHEMBL27461501 0.67 HDAC3 (0.52) KMT2AALDH1A1CYP3A4CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096922-A1 Novel Sulfonamide derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-04-24 US disclosed
EP-1736467-A1 NOVEL SULFONAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096922-A1 Novel Sulfonamide derivative NR4A1, NR4A2, NR4A3 KMT2A 1132/4885TET3 2143/4885FBXL19 3690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.